Sprycel approved in combination with chemo pediatric Ph+ ALL

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA has expanded the indication for Sprycel (dasatinib) tablets to include the treatment of pediatric patients one year of age and older with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia in combination with chemotherapy.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
In This Issue

YOU MAY BE INTERESTED IN

Login